This Week's Lead Thai Beauty: The Crisis Cohort 🇹🇭 Thailand · Insight Rohto Pharmaceutical completed its search on January 7, 2026: fifty-one percent of THANN, a Thai spa brand known for its Japanese-minimalist design and rice bran formulation, signed. The number that preceded the signature — more than 500 Thai companies screened — says more about the opportunity than the deal itself. Rohto was looking for a specific thing. It took five hundred searches to find one. The baht collapsed on July 2, 1997. Thailand called it the Tom Yum Kung Crisis. For the brands that would become the country's premium beauty tier, it was a founding condition. Local ingredients became necessary when imports priced out. Export discipline became survival strategy when the domestic consumer disappeared. HARNN launched in 1999, building with Thai rice bran oil because baht depreciation made it the only rational input. Pañpuri followed in 2003, founder Vorravit Siripark drawing on Ayutthaya-era herbal traditions. THANN followed the same year, after founder Thitipat Suppattranont returned from an Australian MBA and applied what he'd seen of the Aesop model to Thailand's botanical infrastructure. These weren't generic Thai startups — they were Sino-Thai family businesses with the capital patience and trade networks that Chinese diaspora structures provide. The crisis hit them differently. The 1997 Cohort had three members. The wave started in 2018. Tanachira Group paid one billion baht for HARNN. Lakeshore Capital took a majority in Pañpuri the same year. Then the pace accelerated: Kosé Corporation closed its Pañpuri acquisition on December 30, 2024. Rohto signed THANN thirteen days later. Three brands, three buyers, seven years — the entire 1997 Cohort is now under institutional ownership. Rohto's 500-company search produced one signature. The search itself is the signal. What Rohto's sweep mapped is also what it didn't close. Srichand United Dispensary — a heritage brand in its third generation, currently at 1.6 billion baht in annual revenue after 160× revenue growth from a ฿10 million original base — remains independent. So do several smaller brands from the OTOP programme incubated in the same crisis era. The 499 companies Rohto passed on weren't failures; they were founders who hadn't decided yet. That's the window — and it doesn't pause for stragglers. 500+ Thai companies screened by Rohto Pharmaceutical before signing THANN — January 2026 |
Read the full profile → |